Funded Grants

Research studies help us understand neurological health and develop better treatments; however, traditional research is often too slow, too expensive, and excludes people who live far from cities or face systemic barriers. ResearchAlly is changing that.

Innovative methods that enable brain-derived proteins to be measured in blood samples are transforming the field of neurology. For example, it is now possible to use a blood test to help diagnose Alzheimer’s Disease and to monitor treatment in Multiple Sclerosis. This project will establish The University of British Columbia (UBC) Platform for Neurology Biomarker Innovation (PNBI).

Therapeutic breakthroughs in Huntington Disease (HD), Alzheimer’s Disease (AD), Parkinson Disease (PD), and other neurodegenerative disorders have been accelerated by access to generously donated human samples. The HD Biobank at the University of British Columbia focuses on neurodegenerative disorders and is a leader in the collection of HD samples globally.

Amyotrophic Lateral Sclerosis (ALS) is a fatal disease that progressively destroys motor neurons, leading to paralysis and death, with no current cure.

Amyotrophic Lateral Sclerosis (ALS) is a progressive disease that destroys the motor neurons needed for movement, speech, and breathing, but new research shows that other spinal cord cells called interneurons may be affected even earlier.

Personalized Modeling and Optimization of Transcranial Temporal Interference Stimulation in Major Depressive Disorder

The Role of the Hypocretin-Dorsal Raphe Nucleus Circuit in Chronic Social Isolation and Acute Social Stress

Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD) are devastating diseases in which a protein called TDP-43 ends up in the wrong part of the cell, disrupting its normal role in managing RNA.

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes muscle weakness and paralysis, partly due to the buildup of protein aggregates in nerve cells.